Integral Diagnostics (IDX) AGM 2025 summary

Opening remarks and agenda

• Meeting commenced with acknowledgment of traditional land owners and confirmation of quorum.

• Hybrid format enabled both in-person and virtual participation, with voting and Q&A procedures outlined.

• Agenda included addresses from the Chair and CEO, followed by formal voting on resolutions.

Board and executive committee updates

• Introduction of directors, including new board members Laura McBain, Kevin Shaw, and Manish Mittal.

• CEO Dr. Ian Kadish announced his retirement at the end of FY26; board is finalizing recruitment for his successor.

• Board and committees strengthened governance and oversight, especially post-merger.

• Two new Non-Executive Directors joined the Board from Capitol Health.

• Appointment of a Radiologist Director to ensure specialist medical input in decision-making.

Financial performance review

• FY25 revenue grew to AUD 628 million, a 33.7% increase, with operating EBITDA margin at 22.0%.

• Operating EBITDA rose to AUD 140.0 million in FY25, with margins improving from 19.3% to 22.0%.

• Operating free cash flow rose 42.9% to $80 million; net debt to EBITDA reduced to 2.6x.

• Merger with Capitol Health delivered $7 million in cost synergies in FY25, with $14 million expected by year-end.

• Diluted earnings per share grew from 7.6 cents in FY22 to 10.2 cents in FY25.